48,830
edits
Difference between revisions of "Programmed cell death 1"
Jump to navigation
Jump to search
→IHC
(→Drugs) |
(→IHC) |
||
| Line 33: | Line 33: | ||
==IHC== | ==IHC== | ||
*There is no standard PD-1 antibody; each drug company has its own clone. | *There is no standard PD-1 antibody; each drug company has its own clone. | ||
*PD-L1 28-8: provides prognostic inflammation, may benefit without staining.<ref>{{Cite journal | last1 = Borghaei | first1 = H. | last2 = Paz-Ares | first2 = L. | last3 = Horn | first3 = L. | last4 = Spigel | first4 = DR. | last5 = Steins | first5 = M. | last6 = Ready | first6 = NE. | last7 = Chow | first7 = LQ. | last8 = Vokes | first8 = EE. | last9 = Felip | first9 = E. | title = Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. | journal = N Engl J Med | volume = 373 | issue = 17 | pages = 1627-39 | month = Oct | year = 2015 | doi = 10.1056/NEJMoa1507643 | PMID = 26412456 }}</ref> | |||
==See also== | ==See also== | ||